We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Diffusion Abnormality Index Provides Potential Imaging Biomarker to Indicate Brain Tumor Response to Radiation Therapy

By HospiMedica International staff writers
Posted on 18 Feb 2013
A new tool called the diffusion abnormality index (DAI) shows potential as an imaging biomarker to gauge brain tumor response to radiation therapy.

The study’s findings were presented February 9, 2013, at the 2013 Cancer Imaging and Radiation Therapy Symposium, held in Orlando (FL, USA). More...
This Symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North American (RSNA).

The study included 20 patients who had brain metastases and who were treated with whole brain radiotherapy. The 45 lesions among the patients were further categorized as 16 responsive, 18 stable, and 11 progressive. Diffusion measurements were taken prior to radiation treatment, two weeks after the start of treatment and one month after treatment completion. For each patient, a normal tissue apparent diffusion coefficient (ADC) histogram was used to divide the tumor ADC histogram into three regions: low (high cellularity), normal, and high (edema and necrosis) diffusion. Analyzing the complex behavior in ADC of brain metastases from preradiation therapy to two weeks after starting treatment, investigators developed a new diffusion index, the DAI, which included both low and high ADC contributions, for prediction of post-treatment tumor response.

Sensitivity and specificity of the change in DAI from pre- to the end of therapy were evaluated and compared with the changes in gross tumor volume from pretreatment to the end of therapy. The changes were helpful in predicting nonresponsive lesions post-treatment. Early prediction of brain tumor response to radiation therapy is vital in providing the most appropriate radiation doses to each lesion.

“While this review included a small number of patients, the data demonstrate that DAI may be a good biomarker to predict brain tumor response,” said lead study author Reza Farjam, a PhD candidate in biomedical engineering focused on cancer functional imaging at the University of Michigan (Ann Arbor, MI, USA). “Further study of this method is needed to improve early prediction of tumor response to radiation therapy and to help us provide brain cancer patients with more accurate information about their treatment progress.”

Related Links:

University of Michigan




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Glucose Meter
StatStrip®
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel

Patient-Specific Artery-on-a-Chip Refines Stroke Risk Stratification

Predicting which patients will experience an ischemic stroke remains challenging because clot detachment and travel differ widely among individuals. Risk assessment often centers on arterial narrowing, yet that approach overlooks complex flow forces that drive thrombosis and embolization. Missed risk can delay preventive... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.